Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22539603 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL3861785 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL5271075 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL485162 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL23937267 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL13041496 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL718121 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL22539510 | 0.79 | GAA (0.59) | SMN1; SMN2TP53GAAPOLBALDH1A1 | |
| SCHEMBL6983298 | 0.79 | MAPT (0.68) | GAAPOLBALDH1A1NPC1TSHR | |
| SCHEMBL6505723 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| CN-1309561-A | Therapeutic agent for erectile dysfunction | MOCHIDA PHARM CO LTD (JP) | 2001-08-22 | — | — | CN | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |